The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its ability to bind recombinant rat VEGF C in a functional solid phase binding assay. Immobilised recombinant human sVEGFR 3/Fc at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
% SDS-PAGE. Purity assessed by SDS page followed by Silver stain.
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute in PBS or medium to a concentration not lower than 100 µg/ml.
Receptor for VEGFC. Has a tyrosine-protein kinase activity.
Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.